Abstract 613P
Background
Physicians have frequent interactions with the pharmaceutical industry (pharma), however, there is concern for possible corporate influence on physicians’ prescribing behaviours. We sought to understand perceptions and interactions between pharma and medical oncologists (MO), in comparison with infectious diseases (ID) physicians.
Methods
We conducted an anonymous online cross-sectional survey of Australian MO and ID physicians comparing self-reported interactions and attitudes with pharma. An additional survey was undertaken at Tan Tock Seng Hospital, Singapore.
Results
A total of 204 Australian and Singaporean physicians were surveyed including 102 oncologists and 102 ID physicians. Demographics including age, gender and years of practice between the two Australian specialties were similar, with an exception that most ID physicians had mainly public work (95% vs. 78% for oncologists, p<0.001). Oncologists had more frequent contact with pharma, the majority (69%) negotiating compassionate access for patients on a monthly/annual basis, compared with ID physicians who had never done so (45%), p<0.001. More ID physicians had never attended a sponsored meeting (15% ID vs. 27% MO respectively, p=0.01) or received travel/accommodation grants from pharma (42% ID vs. 85% MO respectively, p<0.001). However, most physicians (92%) had never received gifts from pharma, with no difference between groups (p=0.17). Most Australian oncologists believed that interacting with pharma was overall beneficial for patient care (78%) compared to ID physicians (34%, p<0.001). This statement was shared by 71% of Singaporean oncologists. Similar rates of Australian oncologists and ID physicians (83% vs. 88%, respectively) felt comfortable for patients to know the details of their interactions with pharma, however, only 57% of Singaporean oncologists agreed with this statement. Most Australian respondents (77%) agreed that there was strong public skepticism of these interactions (p=0.35).
Conclusions
Medical oncologists had more interactions with pharma than ID physicians and were more likely to believe that this was overall beneficial to patient care despite the negative public perception associated with this.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P.L. Chia: Financial Interests, Personal, Advisory Board: Merck, Roche, Pfizer, Amgen; Financial Interests, Institutional, Research Funding: Merck, Roche, Pfizer, Amgen. T. John: Financial Interests, Personal, Invited Speaker, Speaker tour Vietnam: AstraZeneca; Financial Interests, Personal, Invited Speaker, CTIO: Merck Sharp Dohme; Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Bayer, Specialised Therapeutics; Financial Interests, Institutional, Advisory Board: Roche, Novartis, Pfizer, Amgen, Takeda, PharmaMar; Financial Interests, Personal, Other, Speaker/Chair: ACE Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract